News & Updates

In the primary analysis of the expanded-access ZUMA-18 trial, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) demonstrated a high level of efficacy in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Adjuvant treatment with alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, significantly improved disease-free survival (DFS) better than platinum-based chemotherapy at 2 years in Asian patients with early-stage, completely resected ALK-positive non–small cell lung cancer (ALK+ NSCLC) in an exploratory analysis of the phase III ALINA trial.

A panel discussion titled ‘A Breath Of Fresh Hope’ was recently held at Petaling Jaya. The discussion was a collaboration between Lung Cancer Network Malaysia (LCNM) and Roche (Malaysia) Sdn Bhd’s pharmaceutical division

Daily treatment with the immunomodulatory agent pomalidomide for 6 months significantly reduced severe nosebleeds in patients with hereditary haemorrhagic telangiectasia (HHT) in the double-blind, randomized, placebo-controlled PATH-HHT trial.

The full analysis of the phase III COMMANDS trial continues to demonstrate the superiority of luspatercept over epoetin alfa for the treatment of erythropoiesis-stimulating agent (ESA)-naïve patients with transfusion-dependent lower-risk myelodysplastic syndromes (TD LR-MDS).

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.